JP2014517808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014517808A5 JP2014517808A5 JP2013558205A JP2013558205A JP2014517808A5 JP 2014517808 A5 JP2014517808 A5 JP 2014517808A5 JP 2013558205 A JP2013558205 A JP 2013558205A JP 2013558205 A JP2013558205 A JP 2013558205A JP 2014517808 A5 JP2014517808 A5 JP 2014517808A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- aryl
- halo
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 5
- 229910005965 SO 2 Inorganic materials 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 229940002612 prodrug Drugs 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 230000002132 lysosomal effect Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 2
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 2
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 108091000114 ceramide glucosyltransferase Proteins 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000009796 Gangliosidoses Diseases 0.000 claims 1
- 102000004547 Glucosylceramidase Human genes 0.000 claims 1
- 108010017544 Glucosylceramidase Proteins 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 125000003302 alkenyloxy group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002641 enzyme replacement therapy Methods 0.000 claims 1
- 201000006440 gangliosidosis Diseases 0.000 claims 1
- 150000002339 glycosphingolipids Chemical class 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- -1 isopropenylphenyl Chemical group 0.000 claims 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003852 triazoles Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161454034P | 2011-03-18 | 2011-03-18 | |
| US61/454,034 | 2011-03-18 | ||
| US201261590711P | 2012-01-25 | 2012-01-25 | |
| US61/590,711 | 2012-01-25 | ||
| PCT/US2012/029417 WO2012129084A2 (en) | 2011-03-18 | 2012-03-16 | Glucosylceramide synthase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055577A Division JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014517808A JP2014517808A (ja) | 2014-07-24 |
| JP2014517808A5 true JP2014517808A5 (cg-RX-API-DMAC10.html) | 2015-04-23 |
| JP6117708B2 JP6117708B2 (ja) | 2017-04-19 |
Family
ID=46879977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558205A Active JP6117708B2 (ja) | 2011-03-18 | 2012-03-16 | グルコシルセラミド合成酵素阻害剤 |
| JP2017055577A Active JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055577A Active JP6420860B2 (ja) | 2011-03-18 | 2017-03-22 | グルコシルセラミド合成酵素阻害剤 |
Country Status (39)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2685986T (lt) * | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
| AU2019222801B2 (en) * | 2012-09-11 | 2021-02-18 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| MA37975B2 (fr) * | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| TW201900625A (zh) * | 2013-03-15 | 2019-01-01 | 美商健臻公司 | 製備葡糖基神經醯胺合成酶抑制劑之方法 |
| JO3713B1 (ar) * | 2013-03-15 | 2021-01-31 | Genzyme Corp | أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت |
| CN104418851A (zh) * | 2013-09-02 | 2015-03-18 | 上海龙翔生物医药开发有限公司 | 奎宁环衍生物的制备方法及纯化方法 |
| EP3079695B1 (en) * | 2013-12-11 | 2021-03-17 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| CN106659697B (zh) * | 2014-05-30 | 2022-03-29 | 斯菲叶尔制药私有公司 | 作为抗结核剂的化合物 |
| ES2856898T3 (es) | 2015-02-02 | 2021-09-28 | Univ Michigan Regents | Inhibidores de glucosilceramida sintasa y métodos terapéuticos que usan los mismos |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017004408A1 (en) * | 2015-07-01 | 2017-01-05 | Northwestern University | Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity |
| CN108290855A (zh) * | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| AU2017238769A1 (en) | 2016-03-25 | 2018-11-15 | Genzyme Corporation | Biomarkers of proteopathies and uses thereof |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| US11001891B2 (en) | 2016-11-14 | 2021-05-11 | Berg Llc | Methods for treating Parkinson's disease |
| WO2018122746A1 (en) | 2016-12-28 | 2018-07-05 | Minoryx Therapeutics S.L. | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase |
| BR112019013571A2 (pt) | 2016-12-29 | 2020-01-07 | Minoryx Therapeutics S.L. | Compostos heteroarila e seu uso |
| CN108341822B (zh) * | 2017-01-23 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和应用 |
| WO2019099294A1 (en) * | 2017-11-14 | 2019-05-23 | Merck Sharp & Dohme Corp. | Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| JP2021506920A (ja) | 2017-12-21 | 2021-02-22 | リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用 |
| EP3747885A4 (en) * | 2018-01-31 | 2021-11-03 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| KR102342902B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| KR102233530B1 (ko) * | 2018-11-22 | 2021-03-31 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| KR102342901B1 (ko) * | 2018-11-22 | 2021-12-24 | (주)프로스테믹스 | 엑소좀 및 이의 다양한 용도 |
| PT3920912T (pt) | 2019-02-04 | 2025-09-09 | Genzyme Corp | Tratamento de ciliopatias usando inibidores da glucosilceramida sintase (gcs) |
| SG11202107844UA (en) | 2019-02-04 | 2021-08-30 | Genzyme Corp | Methods for treating symptoms and disorders associated with lysosomal storage diseases |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
| WO2021020363A1 (ja) * | 2019-07-29 | 2021-02-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US11220479B2 (en) | 2019-10-23 | 2022-01-11 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| ES3058346T3 (es) | 2019-11-15 | 2026-03-10 | Yuhan Corp | Derivados que tienen un resto 2,3-dihidro-1H-indeno o 2,3-dihidrobenzofurano o una sal farmacéuticamente aceptable de mismo y composiciones farmacéuticas que comprenden los mismos |
| US12338237B2 (en) | 2019-11-15 | 2025-06-24 | Yuhan Corporation | Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same |
| JP7890737B2 (ja) | 2019-11-25 | 2026-07-15 | ジーティー ゲイン セラピューティクス エスアー | ガラクトセレブロシダーゼの活性の変質に関連する状態におけるアリールおよびヘテロアリール化合物、ならびにそれらの治療的使用 |
| AU2020394602B2 (en) | 2019-11-25 | 2026-05-21 | Gt Gain Therapeutics Sa | Heteroaryl compounds and therapeutic uses thereof in conditions associated with the alteration of the activity of beta-glucocerebrosidase |
| EP4100015A1 (en) | 2020-02-03 | 2022-12-14 | Gain Therapeutics SA | Combination therapy for treating mps1 |
| IL295255A (en) | 2020-02-03 | 2022-10-01 | Genzyme Corp | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| WO2021214771A1 (en) | 2020-04-23 | 2021-10-28 | The Israel Institute of Biological Research (IIBR) | Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases |
| WO2021221953A1 (en) | 2020-04-28 | 2021-11-04 | The Regents Of The University Of Michigan | Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same |
| IL300090A (en) | 2020-07-24 | 2023-03-01 | Genzyme Corp | Pharmaceutical preparations containing VENGLUSTAT |
| US20230372313A1 (en) * | 2020-07-30 | 2023-11-23 | Genzyme Corporation | Methods for reducing glycosphingolipid concentration in brain tissue and methods of treatment of neurodegenerative diseases involving the same |
| WO2022240116A1 (en) * | 2021-05-11 | 2022-11-17 | Yuhan Corporation | Novel compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same |
| WO2023042177A1 (en) | 2021-09-20 | 2023-03-23 | Gt Gain Therapeutics Sa | Enantiomers of 5-((7-chloroisoquinolin-1-yl)amino)-n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)picolinamide |
| WO2023239892A1 (en) * | 2022-06-10 | 2023-12-14 | Arkuda Therapeutics | Compounds for modulation of cd68 and uses thereof |
| IL319915A (en) * | 2022-10-24 | 2025-05-01 | Yuhan Corp | Improved processes for the preparation of dimethyl-3,2-dihydro-1H-indene derivatives |
| KR20240057364A (ko) * | 2022-10-24 | 2024-05-02 | 주식회사유한양행 | 다이메틸-2,3-다이하이드로-1h-인덴 유도체의 신규 염 및 이의 제조방법 |
| CN120417900A (zh) | 2022-12-01 | 2025-08-01 | 建新公司 | 文鲁司他与cyp3a4的强或中度抑制剂的组合 |
| AU2023418678A1 (en) | 2022-12-30 | 2025-07-17 | Gt Gain Therapeutics Sa | Method of treating tauopathies |
| CN122122139A (zh) | 2023-11-02 | 2026-05-29 | Gt增益治疗股份有限公司 | 取代的吲哚基化合物、其组合物及其治疗用途 |
| WO2025159544A1 (en) * | 2024-01-26 | 2025-07-31 | Yuhan Corporation | Pharmaceutical composition for preventing or treating gaucher disease |
| WO2025215582A1 (en) | 2024-04-11 | 2025-10-16 | Gt Gain Therapeutics Sa | Substituted pyrazolopyridine and pyrazolopyrimidine compounds and their use |
| WO2025219952A1 (en) | 2024-04-19 | 2025-10-23 | Genzyme Corporation | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders |
| TW202604489A (zh) | 2024-04-19 | 2026-02-01 | 美商健臻公司 | 用於降低患有神經節苷脂儲積症的患者中的疾病相關生物標誌物水準之方法 |
| TW202606667A (zh) | 2024-06-17 | 2026-02-16 | 美商健臻公司 | 使用葡萄糖神經醯胺合成酶抑制劑治療患有肝損傷之受試者的方法 |
| CN118496159B (zh) * | 2024-07-18 | 2024-09-24 | 广州医科大学附属市八医院 | 一种化合物在制备具有预防和/或治疗肝纤维化作用的药物中的应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (cg-RX-API-DMAC10.html) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| WO1988002477A1 (en) * | 1986-10-03 | 1988-04-07 | Micro Motion, Inc. | Density insensitive coriolis mass flow rate meter |
| IE63474B1 (en) | 1987-12-24 | 1995-04-19 | Wyeth John & Brother Ltd | Heterocyclic compounds |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| IT1228293B (it) * | 1989-02-06 | 1991-06-07 | Angeli Inst Spa | Benzoderivati di composti eterociclici contenenti azoto. |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| AU685225B2 (en) * | 1994-02-10 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Novel carbamate derivative and medicinal composition containing the same |
| JPH08198751A (ja) * | 1995-01-19 | 1996-08-06 | Yamanouchi Pharmaceut Co Ltd | カルバメート誘導体 |
| JP2000500139A (ja) * | 1995-11-08 | 2000-01-11 | アメリカン・ホーム・プロダクツ・コーポレイション | １−アザビシクロヘプタン誘導体およびそれらの医薬用途 |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| EP1345937B1 (en) * | 2000-12-22 | 2005-09-28 | Almirall Prodesfarma AG | Quinuclidine carbamate derivatives and their use as m3 antagonists |
| DE60216830T2 (de) * | 2001-02-06 | 2007-06-14 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen |
| JP2003267977A (ja) * | 2002-03-14 | 2003-09-25 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体 |
| ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
| ES2393331T3 (es) * | 2002-07-17 | 2012-12-20 | Actelion Pharmaceuticals Ltd. | Derivados de piperidintriol como inhibidores de la glucosiliceramida sintasa |
| AU2003248122A1 (en) * | 2002-07-25 | 2004-02-16 | Kotobuki Pharmaceutical Co., Ltd. | Sodium channel inhibitor |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| ATE378048T1 (de) * | 2002-12-06 | 2007-11-15 | The Feinstein Inst Medical Res | Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2007186422A (ja) * | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
| JP2008504282A (ja) * | 2004-06-23 | 2008-02-14 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | コリンレセプターの薬理活性により腸閉塞を処置する方法 |
| BRPI0517701A8 (pt) | 2004-11-10 | 2018-01-23 | Genzyme Corp | métodos de tratamento de diabetes mellitus |
| US20090318491A1 (en) * | 2006-01-27 | 2009-12-24 | Yale Univeristy | Cytisine and Acetylcholine Analogs and Methods of Treating Mood Disorders |
| US7840109B2 (en) * | 2006-08-14 | 2010-11-23 | Adc Telecommunications, Inc. | Factory spliced cable assembly |
| EP2211856A4 (en) * | 2007-11-29 | 2011-02-09 | Hospital For Sick Children | COMPOSITIONS AND METHODS FOR TREATING LYSOSOMAL DISORDER |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| JP2011529500A (ja) * | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
| US20110237538A1 (en) * | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| WO2010091104A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| WO2010091164A1 (en) * | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Inhibitors of glucosylceramide synthase |
| US20100242354A1 (en) * | 2009-06-09 | 2010-09-30 | Sundrop Fuels, Inc. | Systems and methods for reactor chemistry and control |
| CA2773133A1 (en) | 2009-08-28 | 2011-03-03 | Edward H. Schuchman | Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| LT2685986T (lt) * | 2011-03-18 | 2020-03-10 | Genzyme Corporation | Gliukozilceramido sintazės slopiklis |
-
2012
- 2012-03-16 LT LTEP12760259.7T patent/LT2685986T/lt unknown
- 2012-03-16 BR BR122019017719-8A patent/BR122019017719B1/pt active IP Right Grant
- 2012-03-16 RU RU2018104472A patent/RU2018104472A/ru not_active Application Discontinuation
- 2012-03-16 CN CN201610884699.1A patent/CN107080747B/zh active Active
- 2012-03-16 PL PL19207540.6T patent/PL3673906T3/pl unknown
- 2012-03-16 AU AU2012231275A patent/AU2012231275A1/en not_active Abandoned
- 2012-03-16 FI FIEP19207540.6T patent/FI3673906T3/fi active
- 2012-03-16 UA UAA201312420A patent/UA118248C2/uk unknown
- 2012-03-16 PL PL12760259T patent/PL2685986T3/pl unknown
- 2012-03-16 TW TW105121161A patent/TWI634119B/zh active
- 2012-03-16 TW TW101109086A patent/TWI546301B/zh active
- 2012-03-16 EP EP12760259.7A patent/EP2685986B1/en active Active
- 2012-03-16 HU HUE12760259A patent/HUE047888T2/hu unknown
- 2012-03-16 UY UY33958A patent/UY33958A/es not_active Application Discontinuation
- 2012-03-16 EP EP19207540.6A patent/EP3673906B1/en active Active
- 2012-03-16 MX MX2013010710A patent/MX365245B/es active IP Right Grant
- 2012-03-16 ES ES12760259T patent/ES2774293T3/es active Active
- 2012-03-16 CR CR20190034A patent/CR20190034A/es unknown
- 2012-03-16 RU RU2013146550A patent/RU2645675C2/ru active
- 2012-03-16 PE PE2013002075A patent/PE20140412A1/es active IP Right Grant
- 2012-03-16 CN CN201280024127.6A patent/CN103917094B/zh active Active
- 2012-03-16 LT LTEP19207540.6T patent/LT3673906T/lt unknown
- 2012-03-16 EP EP25169140.8A patent/EP4559918A3/en active Pending
- 2012-03-16 PY PY201201212975A patent/PY1212975A/es unknown
- 2012-03-16 RS RS20250761A patent/RS67073B1/sr unknown
- 2012-03-16 SI SI201232091T patent/SI3673906T1/sl unknown
- 2012-03-16 KR KR1020137027592A patent/KR101987736B1/ko active Active
- 2012-03-16 MY MYPI2013003389A patent/MY173998A/en unknown
- 2012-03-16 DK DK19207540.6T patent/DK3673906T3/da active
- 2012-03-16 PT PT192075406T patent/PT3673906T/pt unknown
- 2012-03-16 PH PH1/2013/501944A patent/PH12013501944A1/en unknown
- 2012-03-16 DK DK12760259.7T patent/DK2685986T3/da active
- 2012-03-16 PT PT127602597T patent/PT2685986T/pt unknown
- 2012-03-16 CA CA2830540A patent/CA2830540C/en active Active
- 2012-03-16 HR HRP20250907TT patent/HRP20250907T1/hr unknown
- 2012-03-16 AR ARP120100873 patent/AR085425A1/es active IP Right Grant
- 2012-03-16 SI SI201231727T patent/SI2685986T1/sl unknown
- 2012-03-16 MX MX2018007961A patent/MX368340B/es unknown
- 2012-03-16 JP JP2013558205A patent/JP6117708B2/ja active Active
- 2012-03-16 WO PCT/US2012/029417 patent/WO2012129084A2/en not_active Ceased
- 2012-03-16 RS RS20200222A patent/RS59963B1/sr unknown
- 2012-03-16 HR HRP20200226TT patent/HRP20200226T1/hr unknown
- 2012-03-16 HU HUE19207540A patent/HUE072576T2/hu unknown
- 2012-03-16 ES ES19207540T patent/ES3037907T3/es active Active
- 2012-03-16 MA MA36299A patent/MA35023B1/fr unknown
- 2012-03-16 BR BR112013023774-0A patent/BR112013023774B1/pt active IP Right Grant
-
2013
- 2013-09-17 CL CL2013002688A patent/CL2013002688A1/es unknown
- 2013-09-17 DO DO2013000209A patent/DOP2013000209A/es unknown
- 2013-09-17 IL IL228514A patent/IL228514B/en active IP Right Grant
- 2013-09-17 NI NI201300083A patent/NI201300083A/es unknown
- 2013-09-18 ZA ZA2013/07016A patent/ZA201307016B/en unknown
- 2013-09-18 US US14/030,725 patent/US9139580B2/en active Active
- 2013-09-18 GT GT201300215A patent/GT201300215A/es unknown
- 2013-09-18 MX MX2019008428A patent/MX2019008428A/es unknown
- 2013-10-17 EC ECSP13012978 patent/ECSP13012978A/es unknown
- 2013-10-17 CO CO13246820A patent/CO6801749A2/es active IP Right Grant
-
2014
- 2014-08-28 US US14/471,958 patent/US9126993B2/en active Active
-
2015
- 2015-08-25 US US14/835,402 patent/US20160207933A1/en not_active Abandoned
-
2016
- 2016-10-14 AU AU2016244305A patent/AU2016244305B2/en active Active
-
2017
- 2017-03-22 JP JP2017055577A patent/JP6420860B2/ja active Active
-
2019
- 2019-08-15 US US16/542,166 patent/US20200048266A1/en not_active Abandoned
-
2021
- 2021-04-27 US US17/242,016 patent/US20210261557A1/en not_active Abandoned
-
2025
- 2025-10-16 US US19/360,505 patent/US20260167645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018104472A (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| JP2015527406A5 (cg-RX-API-DMAC10.html) | ||
| KR101472248B1 (ko) | 뒤시엔느 근이영양증의 치료 | |
| JP2013529210A5 (cg-RX-API-DMAC10.html) | ||
| JP2010502730A5 (cg-RX-API-DMAC10.html) | ||
| JP2009263394A5 (cg-RX-API-DMAC10.html) | ||
| JP2013510178A5 (cg-RX-API-DMAC10.html) | ||
| PH12012502572A1 (en) | Novel nicotinamide derivative or salt thereof | |
| AR083542A1 (es) | Piperidin-4-il-azetidin diamidas como inhibidores de monoacilglicerol lipasa | |
| JP2009526830A5 (cg-RX-API-DMAC10.html) | ||
| PE20061198A1 (es) | Derivados de pirazol como inhibidores de cdk y gsk | |
| MX2009010491A (es) | Derivado heterociclico de 5 miembros y su uso para propositos medicos. | |
| JP2011513305A5 (cg-RX-API-DMAC10.html) | ||
| JP2010529147A5 (cg-RX-API-DMAC10.html) | ||
| AR060807A1 (es) | Derivados de arilaminopiridina heteroaril - susutituidos como inhibidores de mek | |
| PT2133332E (pt) | Derivado de (aza)indole e sua utilização para fins médicos | |
| JP2017537940A5 (cg-RX-API-DMAC10.html) | ||
| JP2013509392A5 (cg-RX-API-DMAC10.html) | ||
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20120834A1 (es) | Derivados de furopirimidindiona como moduladores de trpa1 | |
| AR066817A1 (es) | Inhibidores de la glucosilceramida sintasa del tipo 2-acilaminopropanol | |
| NZ593712A (en) | Intermediates for synthesising nucleoside aryl phosphoramidates | |
| JP2013533253A5 (cg-RX-API-DMAC10.html) | ||
| PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
| JP2012530758A5 (cg-RX-API-DMAC10.html) |